At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 152 enrolled
Drug / intervention
ARV-471 +2 moredrug
Likely dose
ARV-471 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting
In Brief
A Phase 2 clinical trial evaluating ARV-471, Anastrozole, and 1 other intervention for Breast Cancer. Completed, enrolled 152 participants across 49 sites in 4 countries.
Detailed Summary
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGeorgia, Germany, Spain, United States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartFeb 2023
Primary CompletionJul 2024
Study CompletionJul 2024
TodayJul 2026
First PostedSep 22, 2022
Enrollment StartFeb 15, 2023
Primary CompletionJul 13, 2024
Study CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.8 years ago
Interventions
ARV-471drug
100 mg tablet
Anastrozoledrug
1 mg tablet
Surgical resection of breast tumorprocedure
Surgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)